Recent technology advancements have enabled the opportunity to increase the efficiency, efficacy and safety of gene and cell-based medicines for a multitude of genetic disorders. To date, a major challenge facing the field has been the ability to deliver therapeutic genes to affected cell types. In this blog, Sarah Haecker Meeks and Michael Roberts from Synpromics outline the ways in which gene medicines can be optimized to overcome this barrier.Read More
High content screeening (HCS) has become a staple tool for scientists trying to find out how molecules alter our cells' biological systems. The huge volume of data that HCS produces is both its strength and weakness. As assays become more complex, companies like Genedata are turning to AI-based approaches to help streamline HCS analysis. I spoke to Genedata's Head of Science, Dr. Stephan Steigele, to find out more.Read More
Life science businesses are facing growing demand to keep pace in an era of fast-evolving technology. By recognizing the potential challenges, a growing number of companies are leveraging the resources and creativity of their suppliers. We took a look at the landscape of optofluidics R&D.Read More
We recently spoke to Alexis Peyroles, CEO at OSE Immunotherapeutics to hear more about the findings of their recent study, describing, for the first time ever, the in vivo MOA of interleukin 7 receptor alpha (IL-7Rα) monoclonal antibodies, suggesting therapeutic efficacy in controlling chronic inflammation.Read More
NeuroBo Pharmaceuticals’ first lead candidate, NB-01, is positioned as a potential treatment for diabetic neuropathic pain. The candidate, which in 2018 will move into a phase III clinical trial, uses extracts of two species of the plant genus Dioscorea, used in traditional medicine for centuries, but never yet subject to systematic study. We caught up with NeuroBo’s Mark Versavel and Nandan Padukone to find out more.
Gold nanorods are increasingly being used in diagnostic applications, such as lateral flow assays. To learn more, we got in touch with Darren Rowles, CEO of Sona Nanotech Inc. who provides insights on diagnostic industry trends, and tells us about the source, application and production process of gold nanoparticles.Read More
Liquid biopsy is a less invasive approach compared to traditional surgical biopsies. By collecting a simple blood sample and analyzing circulating tumor DNA (ctDNA), cancer researchers and healthcare professionals can access a myriad of information about a patient’s tumor.Read More
Dioxins pose a significant risk to human health and are carcinogenic even at trace levels. Consumption of contaminated food is a common route of dioxin exposure. To ensure consumer safety, accurate detection and quantification of dioxins in food and animal feed is essential.
A recent assessment of the success of the drug development process put the percentage of phase I programs that make it to approval at 13.8%. That figure points to a crisis of attrition within the industry. Netramark, a Toronto-based start-up claim they have a machine learning-powered solution to that crisisRead More